Stock Update (NYSE:BAX): Novo Nordisk, Baxter clash over haemophilia drug patent

[Reuters] – Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent . . . → Read More: Stock Update (NYSE:BAX): Novo Nordisk, Baxter clash over haemophilia drug patent Similar Articles: Company Update: Baxter International Inc (NYSE:BAX) – Baxter to Webcast Annual Meeting of Shareholders Company Update (NYSE:LLY): Eli Lilly loses Alimta drug patent case in Germany to Actavis Market Update: Gilead Sciences Inc (NASDAQ:GILD) – India rejects Gilead’s Hepatitis C drug patent request